Methylprednisolone Completed Phase 2 Trials for Graft Versus Host Disease (GVHD) / Malignancies / Blood Cancers / Smith-Magenis Syndrome / Chronic Lymphocytic Leukaemia (CLL) / Hodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL) / Leukemias Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01181258Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
NCT00336583Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
NCT00458848Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia
NCT00002785Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia
NCT00022126Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
NCT02176031Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD
NCT00609609Photopheresis for the Treatment of Acute Graft Versus Host Disease